Functional abilities, respiratory and cardiac function in a large cohort of adults with Duchenne muscular dystrophy treated with glucocorticoids
European Journal of Neurology · 2024-06 · 31 (6)
DOI: 10.1111/ene.16267 ↗At a glance
Journal article in European Journal of Neurology, published online on 2024-03-31. Written by Marianela Schiava and 22 co-authors. Institution: John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trusts, Newcastle Upon Tyne, UK. Major MEDLINE topics: Muscular Dystrophy, Duchenne, Glucocorticoids. Cited 16 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background and purpose The transition to adult services, and subsequent glucocorticoid management, is critical in adults with Duchenne muscular dystrophy. This study aims (1) to describe treatment, functional abilities, respiratory and cardiac status during transition to adulthood and adult stages; and (2) to explore the association between glucocorticoid treatment after loss of ambulation (LOA) and late‐stage clinical outcomes.
Methods
This was a retrospective single‐centre study on individuals with Duchenne muscular dystrophy (≥16 years old) between 1986 and 2022. Logistic regression, Cox proportional hazards models and survival analyses were conducted utilizing data from clinical records.
Results
In all, 112 individuals were included. Mean age was 23.4 ± 5.2 years and mean follow‐up was 18.5 ± 5.5 years. At last assessment, 47.2% were on glucocorticoids; the mean dose of prednisone was 0.38 ± 0.13 mg/kg/day and of deflazacort 0.43 ± 0.16 mg/kg/day. At age 16 years, motor function limitations included using a manual wheelchair (89.7%), standing (87.9%), transferring from a wheelchair (86.2%) and turning in bed (53.4%); 77.5% had a peak cough flow
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- John Walton Muscular Dystrophy Research Centre, Newcastle University and Newcastle Hospitals NHS Foundation Trusts, Newcastle Upon Tyne, UK.
- ATOM International Limited, Gateshead, UK.
ORCID profiles: Marianela Schiava, Jordi Díaz-Manera, Cathy Turner, Michela Guglieri
Cite
APA
Schiava, M., Lofra, R. M., Bourke, J. P., Díaz-Manera, J., James, M. K., Elseed, M. A., Malinova, M., Michel-Sodhi, J., Moat, D., Ghimenton, E., Mccallum, M., Díaz, C. F. B., Mayhew, A., Wong, K., Richardson, M., Tasca, G., Eglon, G., Eagle, M., Turner, C., …, & Guglieri, M. (2024). Functional abilities, respiratory and cardiac function in a large cohort of adults with Duchenne muscular dystrophy treated with glucocorticoids. European Journal of Neurology, 31(6). https://doi.org/10.1111/ene.16267
Vancouver
Schiava M, Lofra RM, Bourke JP, Díaz-Manera J, James MK, Elseed MA, et al. Functional abilities, respiratory and cardiac function in a large cohort of adults with Duchenne muscular dystrophy treated with glucocorticoids. European Journal of Neurology. 2024;31(6). doi:10.1111/ene.16267
BibTeX
@article{Schiava2024,
author = {Schiava, Marianela and Lofra, Robert Muni and Bourke, John P and Díaz-Manera, Jordi and James, Meredith K and Elseed, Maha A and Malinova, Monika and Michel-Sodhi, Jassi and Moat, Dionne and Ghimenton, Elisabetta and Mccallum, Michelle and Díaz, Carla Florencia Bolaño and Mayhew, Anna and Wong, Karen and Richardson, Mark and Tasca, Giorgio and Eglon, Gail and Eagle, Michelle and Turner, Cathy and Heslop, Emma and Straub, Volker and Bettolo, Chiara Marini and Guglieri, Michela},
title = {Functional abilities, respiratory and cardiac function in a large cohort of adults with Duchenne muscular dystrophy treated with glucocorticoids},
journal = {European Journal of Neurology},
year = {2024},
volume = {31},
number = {6},
doi = {10.1111/ene.16267}
}
EUVIMED